Recurrent Clostridium Difficile Infection Clinical Trial
Official title:
A Randomised, Controlled, Open-label Phase III Clinical Trial in Patients With Primary or Recurrent Clostridioides Difficile (CD) Infection, to Evaluate the Efficacy and Safety of Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin.
Verified date | January 2024 |
Source | Mikrobiomik Healthcare Company S.L. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients with microbiota alterations developed after being exposed to antibiotics are especially susceptible to Clostridioides difficile infections (CDI). The incidence and severity of CDI has increased in recent years and CDI recurrences (r-CDI) due to the appearance of new episodes in patients with a previous cured CDI, represent a serious and complex clinical issue. Although antibiotics are the recommended therapy for the first episode of CDI, treatment with oral vancomycin and/or metronidazole often results in significant treatment failure. In addition, the treatment of r-CDI is not adequately standardized, and although the most widely used treatment is the administration of fidaxomicin and bezlotoxumab, its efficacy in patients who already have r-CDI is not proven. In the late years, Fecal Microbiota Transfer (FMT) has emerged as the preferred non-pharmacological treatment to manage CDI with multiple recurrences and recent clinical trials have evaluated its potential efficacy and safety in the treatment of patients with primary CD infection. The objective of this study is to assess the efficacy and safety of the MBK-01 medication, consisting of heterologous lyophilized fecal microbiota capsules coming from healthy donors in comparison to the treatment with Fidaxomicin, in 66 patients with primary or r-CDI.
Status | Completed |
Enrollment | 93 |
Est. completion date | November 15, 2023 |
Est. primary completion date | November 15, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients of both genders, over 18 years. 2. Patients that undergo an episode of CD infection (either the first episode or subsequent recurrences). 3. Presence of an episode of diarrhea defined as =3 stools/24 hours, at the beginning of the episode. 4. Confirmation of the presence of CD toxin A and/or B in faeces, by a direct toxin detection test or by the PCR technique for the detection of toxin/s producing genes, at the start of the episode that is going to be treated in the clinical trial (the toxin test must be positive within 7 days prior to the enrolment of the patient in the trial). Exclusion Criteria: 1. Previous faecal microbiota transfer. 2. Transplanted patients, except those with a solid organ transplant of more than 2 years, with good organ function. 3. Absolute neutrophil count <500 cells /µL at the time of the enrollment in the study. 4. Pregnancy, breastfeeding, or pregnancy intentions over the course of the study. 5. Active treatment with bile acid sequestrants (for instance: cholestyramine). 6. Positive patients for the human immunodeficiency virus (HIV) except those with lymphocytes T CD4 count > 200 cells/µL and viral load less than 20 copies. 7. Swallowing dysfunction or no oral motor coordination. 8. Patient admitted in an intensive care unit or expected to be admitted in an intensive care unit due to serious illness. 9. History of significant medical conditions that, in the opinion of the investigator, would not allow an adequate evaluation or follow-up of the patient. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital General Universitario de Alicante | Alicante | |
Spain | Hospital Universitario de Cruces | Barakaldo | |
Spain | Hospital Clínic de Barcelona | Barcelona | |
Spain | Hospital Quirónsalud Barcelona | Barcelona | |
Spain | Hospital Universitario de Bellvitge | Barcelona | |
Spain | Hospital Universitario de Basurto | Bilbao | |
Spain | Hospital Universitario Reina Sofía | Córdoba | |
Spain | Hospital Universitario de Donostia | Donostia | |
Spain | Hospital Josep Trueta de Gerona | Girona | |
Spain | Hospital San Pedro | Logroño | |
Spain | Hospital General Universitario Gregorio Marañón | Madrid | |
Spain | Hospital Universitario 12 de Octubre | Madrid | |
Spain | Hospital Universitario La Paz | Madrid | |
Spain | Hospital Universitario Puerta de Hierro | Madrid | |
Spain | Hospital Universitario Quirónsalud Madrid | Madrid | |
Spain | Hospital Universitario Ramón y Cajal | Madrid | |
Spain | Hospital Universitario Son Espases | Palma De Mallorca | |
Spain | Hospital Universitario Marqués de Valdecilla | Santander | Cantabria |
Spain | Hospital Universitario y Politécnico La Fe | Valencia | |
Spain | Hospital Universitario de Araba | Vitoria-Gasteiz | |
Spain | Hospital Clínico Universitario Lozano Blesa | Zaragoza |
Lead Sponsor | Collaborator |
---|---|
Mikrobiomik Healthcare Company S.L. |
Spain,
Reigadas E, Bouza E, Olmedo M, Vazquez-Cuesta S, Villar-Gomara L, Alcala L, Marin M, Rodriguez-Fernandez S, Valerio M, Munoz P. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: experience with lyophilized oral capsules. J Hosp Infect. 2020 Jun;105(2):319-324. doi: 10.1016/j.jhin.2019.12.022. Epub 2019 Dec 26. — View Citation
Reigadas E, Olmedo M, Valerio M, Vazquez-Cuesta S, Alcala L, Marin M, Munoz P, Bouza E. Fecal microbiota transplantation for recurrent Clostridium difficile infection: Experience, protocol, and results. Rev Esp Quimioter. 2018 Oct;31(5):411-418. Epub 2018 Sep 14. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Global Absence of diarrhea: Number of episodes of diarrhea (3 or more stools/24 hours) 8 weeks after the start of the treatment | Diarrhea resolution: <3 stools/24 hours for at least 2 consecutive days after the end of the treatment. | 8 weeks after the start of the treatment | |
Primary | Absence of diarrhea: Number of episodes of diarrhea (3 or more stools/24 hours) 72 hours after the start of the treatment | Diarrhea resolution: <3 stools/24 hours for at least 2 consecutive days after the end of the treatment. | 72 hours after the start of the treatment | |
Primary | Absence of diarrhea: Number of episodes of diarrhea (3 or more stools/24 hours) 3 weeks after the start of the treatment | Diarrhea resolution: <3 stools/24 hours for at least 2 consecutive days after the end of the treatment. | 3 weeks after the start of the treatment | |
Primary | Absence of diarrhea: Number of episodes of diarrhea (3 or more stools/24 hours) 3 months after the start of the treatment | Diarrhea resolution: <3 stools/24 hours for at least 2 consecutive days after the end of the treatment. | 3 months after the start of the treatment | |
Primary | Absence of diarrhea: Number of episodes of diarrhea (3 or more stools/24 hours) 6 months after the start of the treatment | Diarrhea resolution: <3 stools/24 hours for at least 2 consecutive days after the end of the treatment. | 6 months after the start of the treatment | |
Secondary | Duration of hospitalisation | Time, in days, that the patient remains in the hospital as a result of CDI. | Up to 8 weeks after the start of the treatment | |
Secondary | Good/bad progress of the patient | A bad progress of the patient is defined as the detection 48-72 hours after the start of the treatment (MBK-01 or Fidaxomicin) of:
A worsening of the diarrhea episode (at least one stool more than at baseline, baseline being understood as the time of the start of the study treatment (fidaxomicin or MBK01)). And, at least, one of the following factors: Increase in C-reactive protein (CRP) value (> 5 % of the baseline value). Increase in white blood cell count (> 5 % of the baseline value). Progression to sepsis: hypotension or organ failure with no other apparent cause. |
Up to 72 hours after the start of the treatment | |
Secondary | Time to recurrence depending on randomisation groups | Recurrence: Reappearance of clinical manifestations of a new CDI episode in a patient with an CDI episode treated and cured in the previous 8 weeks. | Up to 6 months after the start of the treatment | |
Secondary | Duration of treatment | Duration in days of the treatment. | Up to 10 days | |
Secondary | Overall survival | Percentage of patients that are still alive after a defined period of time from the beginning of the treatment. | Up to 6 months after the start of the treatment | |
Secondary | Number of Adverse Events per randomisation group | Number of Adverse Events per randomisation group since baseline. | Up to 6 months after the start of the treatment | |
Secondary | Type of Adverse Events per ramdomisation group | Type of Adverse Events per ramdomisation group since baseline. | Up to 6 months after the start of the treatment | |
Secondary | Number of Serious Adverse Events per ramdomisation group | Number of Serious Adverse Events per ramdomisation group since baseline. | Up to 6 months after the start of the treatment | |
Secondary | Type of Serious Adverse Events per ramdomisation group | Type of Serious Adverse Events per ramdomisation group since baseline. | Up to 6 months after the start of the treatment | |
Secondary | Adverse Events related to the treatment | Adverse Events related to the treatment since baseline. | Up to 6 months after the start of the treatment | |
Secondary | Adverse Event Seriousness | Adverse Event Seriousness since baseline. | Up to 6 months after the start of the treatment | |
Secondary | Adverse Events related to the CDI | Adverse Events related to the CDI since baseline. | Up to 6 months after the start of the treatment | |
Secondary | Mortality associated with CDI | Percentage of patients that die due to CDI after a defined period of time from the beginning of the treatment. | Up to 6 months after the start of the treatment | |
Secondary | Intensive Care Unit admissions (ICU) | Percentage of patients admitted in the ICU after a defined period of time from the beginning of the treatment. | Up to 6 months after the start of the treatment | |
Secondary | Adverse Events of special interest | Adverse Events of special interest since baseline. | Up to 6 months after the start of the treatment | |
Secondary | SF36 questionnaire (The Short Form-36 Health Survey) to evaluate the quality of life | For each dimension (physical functioning, role limits-physical, bodily pain, general health, vitality, social functioning, role limits-emotional, mental health), the scale ranges from 0 (the worst health status for that dimension) to 100 (the best health status). | Day 0, 8 weeks and 6 months after the start of the treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01226992 -
Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04960306 -
Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection
|
Phase 3 | |
Completed |
NCT03462459 -
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection
|
Phase 2 | |
Recruiting |
NCT06237452 -
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
|
Phase 3 | |
Recruiting |
NCT05826418 -
Dietary Optimization of Microbiome Recovery Following Fecal Microbiota Transplantation
|
N/A | |
Completed |
NCT03497806 -
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
|
Phase 2 | |
Suspended |
NCT01202630 -
BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection
|
Phase 3 | |
Terminated |
NCT03973697 -
Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection
|
Phase 2 | |
Completed |
NCT03353506 -
Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection
|
Phase 2 | |
Completed |
NCT01925417 -
Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea
|
Phase 2 | |
Available |
NCT03786900 -
Fecal Microbiota Transplantation (FMT): PRIM-DJ2727
|